Paper Title:
Genistein and Cisplatin, Alone and in Combination, Suppress Growth of Human Ovarian carcinoma Cell Line SKOV3
  Abstract

Recent studies have shown that Genistein can obviously suppress growth of gynecologic carcinoma. In this study we examined whether Genistein and Cisplatin, alone and in combination, exhibited a inhibitory effect on the growth of ovarian carcinoma. SKOV3 cells were treated with 20µM Genistein, 20µM Cisplatin and combination group (G+C) for 24 to 72 hours, antiproliferative effect was tested by MTT method. Apoptosis was evaluated using flow cytometry and transmission electron microscopy. Then the transplanted xenografts were treated with Genistein and Cisplatin, the tumor volume and tumor weight were measured, HE staining were performed for morphologic observation. A time and dose-dependent growth inhibition was observed. When treated the cells with 20µM Genistein, 20µMCisplatin and combination group (G+C), compared with the control group, the growth of cells in different treatment group was inhibited, while the combination of Genistein and Cisplatin showed significant inhibition effect than single agent. When Genistein (0.4mg/kg, s.c.) treated the transplanted xenograft in vivo, the tumor volume and tumor weight decreased, T/C ratio (mean volume of treated group/mean volume of control group) also was reduced compared to untreated group, and extensive necrotic areas in the tumor treated with Genistein and Cisplatin appeared in HE section. A weight loss of nude mice after treatment with Genistein was not significant as compared with the control group. And when treated with Genistein (0.4mg/kg, s.c.) and Cisplatin (4mg/kg, i.v.), it showed a synergistic effect. Genistein and Cisplatin, alone and in combination, suppress cell growth. The combination of Genistein and Cisplatin, as compared to single treated group, caused a synergistic increase in antiproliferative effect on SKOV3 cells. The implication for treatment of ovarian cancer may be combination of Genistein and Cisplatin. Further studies are needed to supply more evidence.

  Info
Periodical
Chapter
Chapter 2: Future Materials Technology and Biomedicine
Edited by
Barry Tan
Pages
222-227
DOI
10.4028/www.scientific.net/AMR.365.222
Citation
L. Tang, L. Yu, "Genistein and Cisplatin, Alone and in Combination, Suppress Growth of Human Ovarian carcinoma Cell Line SKOV3", Advanced Materials Research, Vol. 365, pp. 222-227, 2012
Online since
October 2011
Authors
Export
Price
$32.00
Share

In order to see related information, you need to Login.

In order to see related information, you need to Login.

Authors: Shu Feng Li, Li Hao, Hui Li Tong, Dan Dan Zhao, Yun Qin Yan
New Functional Materials
Abstract:To drink excessively for long time would damage human genital system seriously, nevertheless there is still less researches on the effect of...
116
Authors: Yan Liang, Xiao Jing Wang, Shu Yu Li, Cheberi, Zhi Gang Wang, Dong Jun Liu
Session 2: Materials for Biomedical Engineering Application
Abstract:The mammalian target of rapamycin(mTOR)is a kind of Ser/Thr kinase in mammalian cells. It can recruit and integrate input signals from...
590
Authors: A. Apirakaramwong, Perayot Pamonsinlapatham, S. Techaarpornkul, Praneet Opanasopit, Suwannee Panomsuk, S. Soksawatmaekhin
III. Applications of Biomaterial
Abstract:Chitosan (CS) has a high potential for gene delivery into mammalian cells. However, its uptake mechanism is not well clarified. We...
485
Authors: Jun Yang, Chun Chu, Biao Deng, Sai Liang Ding, Guang Hui Wang, Yong Zhang, Zhi Hua Quan
Chapter 1: New Materials and Advanced Materials
Abstract:Abstract Objective To testify the special cytotoxicity of TGF-alpha-SAP on proliferating vascular smooth muscle cells and endothelial cells....
182
Authors: Shu Jing Wang, Fei Wang, Jia Liu, Shan Jiang, Ning Chen, Lin Liu, Ying Zhao, Xiao Dan Zhang
Chapter 3: Biochemical, Medicine Engineering and Technologies, Applications of Genetic Engineering
Abstract:The direct anti-tumor T-7 peptide of tumstatin was obtained to study its effect on human hepatoma cells (HepG-2) and human umbilical vein...
744